SALT LAKE CITY, UT -- (MARKET WIRE) -- March 27, 2007 -- Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it has initiated a Phase 2 human clinical trial of its therapeutic candidate, Azixa™ (MPC-6827), in patients with melanoma that has spread to the brain.
